* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Leukaemia Section t(20;21)(q13;q22) Atlas of Genetics and Cytogenetics in Oncology and Haematology
Public health genomics wikipedia , lookup
Essential gene wikipedia , lookup
Point mutation wikipedia , lookup
Quantitative trait locus wikipedia , lookup
Non-coding DNA wikipedia , lookup
Epigenetics in learning and memory wikipedia , lookup
Epigenetics of neurodegenerative diseases wikipedia , lookup
Site-specific recombinase technology wikipedia , lookup
Long non-coding RNA wikipedia , lookup
Vectors in gene therapy wikipedia , lookup
Cancer epigenetics wikipedia , lookup
Short interspersed nuclear elements (SINEs) wikipedia , lookup
Gene expression programming wikipedia , lookup
Genomic imprinting wikipedia , lookup
Genome evolution wikipedia , lookup
History of genetic engineering wikipedia , lookup
Primary transcript wikipedia , lookup
Biology and consumer behaviour wikipedia , lookup
Ridge (biology) wikipedia , lookup
Medical genetics wikipedia , lookup
Nutriepigenomics wikipedia , lookup
Minimal genome wikipedia , lookup
Artificial gene synthesis wikipedia , lookup
Oncogenomics wikipedia , lookup
Designer baby wikipedia , lookup
Polycomb Group Proteins and Cancer wikipedia , lookup
Genome (book) wikipedia , lookup
Gene expression profiling wikipedia , lookup
Microevolution wikipedia , lookup
Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Leukaemia Section Short Communication t(20;21)(q13;q22) Jean-Loup Huret Genetics, Dept Medical Information, UMR 8125 CNRS, University of Poitiers, CHU Poitiers Hospital, F86021 Poitiers, France (JLH) Published in Atlas Database: February 2003 Online updated version: http://AtlasGeneticsOncology.org/Anomalies/t2021q13q22ID1264.html DOI: 10.4267/2042/37970 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2003 Atlas of Genetics and Cytogenetics in Oncology and Haematology AML1 Clinics and pathology Location 21q22 DNA/RNA Transcription is from telomere to centromere. Protein Contains a Runt domain and, in the C-term, a transactivation domain; forms heterodimers; widely expressed; nuclear localisation; transcription factor (activator) for various hematopoietic-specific genes. Disease Refractory anemia with excess of blasts and M5- acute non lymphocytic leukemia. Etiology Treatment of a non Hodgkin lymphoma 2 yrs before diagnosis in 1 case. Epidemiology Only 2 male patient cases, aged 38 yrs and 69 yrs. References Cytogenetics Secker-Walker LM, Mehta A, Bain B. Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. Br J Haematol. 1995 Oct;91(2):490501 Cytogenetics morphological Complex karyotypes in 1 case, +10 in the other one. Richkind K, Hromas R, Lytle C, Crenshaw D, Velasco J, Roherty S, Srinivasiah J, Varella-Garcia M. Identification of two new translocations that disrupt the AML1 gene. Cancer Genet Cytogenet. 2000 Oct 15;122(2):141-3 Genes involved and proteins Note The gene in 20q13 is yet unknown, and, because cryptic t(12;21) ETV6 /AML1 are not rare, it is therefore uncertain whether this translocation involve a new AML1 partner. Mathew S, Shurtleff SA, Raimondi SC. Novel cryptic, complex rearrangements involving ETV6-CBFA2 (TEL-AML1) genes identified by fluorescence in situ hybridization in pediatric patients with acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2001 Oct;32(2):188-93 This article should be referenced as such: Huret JL. t(20;21)(q13;q22). Atlas Genet Cytogenet Oncol Haematol. 2003; 7(2):118. Atlas Genet Cytogenet Oncol Haematol. 2003; 7(2) 118